The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand Factor (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF/FVIII in healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharmacodynamics in hemophilia A. Nineteen adult patients (ages 20-62 years, 4 women) with hemophilia A (8 mild, 2 moderate, and 9 severe) received subcutaneous injections of rondaptivon pegol. After an initial fixed dose of 3 mg on days 0 and 4, patients received weekly doses of 2 to 9 mg until day 28. Severe hemophilia A patients underwent sparse-sampling population pharmacokinetics individual profiling after the final dose of rondaptivon pegol. Adverse events, pharmacokinetics, and pharmacodynamics were assessed. FVIII activity and VWF levels were measured. All patients tolerated rondaptivon pegol well. The geometric mean half-life of rondaptivon pegol was 5.4 days and rondaptivon pegol significantly increased VWF levels. In severe hemophilia A, 6 doses of rondaptivon pegol increased the half-lives of 5 different FVIII products from a median of 10.4 hours to 31.1 hours (range, 20.8-56.0 hours). Median FVIII increased from 22% to 48% in mild hemophilia A and from 3% to 7.5% in moderate hemophilia A. Rondaptivon pegol is a first-in-class prohemostatic molecule that extended the half-life of substituted FVIII approximately 3-fold and increased endogenous FVIII levels approximately 2-fold in hemophilia patients. This trial was registered at www.clinicaltrials.gov as #NCT04677803.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Blood - 141(2023), 10 vom: 09. März, Seite 1147-1158 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ay, Cihan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9001-27-8 |
|---|
| Anmerkungen: |
Date Completed 13.03.2023 Date Revised 19.11.2023 published: Print ClinicalTrials.gov: NCT04677803 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2022016571 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346250684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346250684 | ||
| 003 | DE-627 | ||
| 005 | 20231226030954.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2022016571 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346250684 | ||
| 035 | |a (NLM)36108308 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ay, Cihan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The von Willebrand factor-binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.03.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT04677803 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Factor VIII (FVIII) circulates in a noncovalent complex with von Willebrand Factor (VWF), the latter determining FVIII half-life. The VWF-binding aptamer rondaptivon pegol (BT200) increases plasma levels of VWF/FVIII in healthy volunteers. This trial assessed its safety, pharmacokinetics, and pharmacodynamics in hemophilia A. Nineteen adult patients (ages 20-62 years, 4 women) with hemophilia A (8 mild, 2 moderate, and 9 severe) received subcutaneous injections of rondaptivon pegol. After an initial fixed dose of 3 mg on days 0 and 4, patients received weekly doses of 2 to 9 mg until day 28. Severe hemophilia A patients underwent sparse-sampling population pharmacokinetics individual profiling after the final dose of rondaptivon pegol. Adverse events, pharmacokinetics, and pharmacodynamics were assessed. FVIII activity and VWF levels were measured. All patients tolerated rondaptivon pegol well. The geometric mean half-life of rondaptivon pegol was 5.4 days and rondaptivon pegol significantly increased VWF levels. In severe hemophilia A, 6 doses of rondaptivon pegol increased the half-lives of 5 different FVIII products from a median of 10.4 hours to 31.1 hours (range, 20.8-56.0 hours). Median FVIII increased from 22% to 48% in mild hemophilia A and from 3% to 7.5% in moderate hemophilia A. Rondaptivon pegol is a first-in-class prohemostatic molecule that extended the half-life of substituted FVIII approximately 3-fold and increased endogenous FVIII levels approximately 2-fold in hemophilia patients. This trial was registered at www.clinicaltrials.gov as #NCT04677803 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a von Willebrand Factor |2 NLM | |
| 650 | 7 | |a Factor VIII |2 NLM | |
| 650 | 7 | |a 9001-27-8 |2 NLM | |
| 650 | 7 | |a Hemostatics |2 NLM | |
| 700 | 1 | |a Kovacevic, Katarina D |e verfasserin |4 aut | |
| 700 | 1 | |a Kraemmer, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Schoergenhofer, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Gelbenegger, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Firbas, Christa |e verfasserin |4 aut | |
| 700 | 1 | |a Quehenberger, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Jilma-Stohlawetz, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, James C |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Shuhao |e verfasserin |4 aut | |
| 700 | 1 | |a Beliveau, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Koenig, Franz |e verfasserin |4 aut | |
| 700 | 1 | |a Iorio, Alfonso |e verfasserin |4 aut | |
| 700 | 1 | |a Jilma, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Derhaschnig, Ulla |e verfasserin |4 aut | |
| 700 | 1 | |a Pabinger, Ingrid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 141(2023), 10 vom: 09. März, Seite 1147-1158 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:10 |g day:09 |g month:03 |g pages:1147-1158 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2022016571 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2023 |e 10 |b 09 |c 03 |h 1147-1158 | ||